Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01684943 · ClinicalTrials.gov registry record · NA

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

A NA study of Type 1 Diabetes, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT01684943 is a NA study of Type 1 Diabetes that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01684943, a NA study of Type 1 Diabetes, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects. Additionally, the investigators will perform a preliminary feasibility evaluation of a minimally invasive continuous insulin monitoring (CIM) device and its use to derive PK parameters in human subjects.

Conditions Studied

Interventions

  • OTHER Multiplex pharmacokinetic profiling
  • OTHER Continuous insulin monitoring

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2010-07
Est. Completion 2017-12
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01684943

The ClinicalTrials.gov registry entry for NCT01684943 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Multiplex pharmacokinetic profiling is the first listed.

NCT01684943 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01684943 about?

NCT01684943 is a clinical study titled "Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling". The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects. Additionally, the investigators will perform a preliminary feasibility evaluati...

What is the current status of trial NCT01684943?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2010-07. Estimated completion is 2017-12.

What conditions does trial NCT01684943 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT01684943?

The interventions under investigation include: Multiplex pharmacokinetic profiling (OTHER), Continuous insulin monitoring (OTHER).

Who is sponsoring clinical trial NCT01684943?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01684943 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.